# Beken Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beken-bio

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.beken.bio
- Latest round: Seed (Dec 10, 2025)
- Investors on record: 4

## About

Beken Bio, Inc. is a US-based biotechnology firm incorporated in 2020, by CEO and founder Christopher Millan, focused on advancing liquid biopsy technology for early cancer detection, utilizing proprietary innovations to improve diagnostic accuracy and patient outcomes.Beken Bio develops minimally invasive liquid biopsies that leverage its 3D REVEAL™ engine to identify novel cancer biomarkers in blood samples. Headquartered in San Diego, US, the company has undertaken strategic advancements in its technology. The firm has closed one funding deal, In December 2025, Beken Bio, Inc. raised seed funding fromTulane Ventures, Boot64, New Orleans BioFund and 1834 Ventures. Beken Bio specializes in the development of minimally invasive liquid biopsies, utilizing its proprietary 3D REVEAL™ engine to diagnose cancer at its earliest stages. This innovative technology identifies novel cancer biomarkers present in the blood before symptoms manifest, enhancing early detection capabilities. The primary objective of Beken Bio’s offerings is to empower healthcare providers with accurate diagnostic tools, facilitating timely and effective treatment interventions for patients. The company targets a broad array of clients, including hospitals, diagnostic laboratories, and oncologists, focusing on markets in North America, Europe, and select regions in Asia. By delivering reliable diagnostic tests, Beken Bio aims to reduce cancer-related mortality rates and shift the paradigm towards proactive cancer management.The revenue model of Beken Bio is structured around partnerships with healthcare providers and institutions that integrate its diagnostic solutions into their patient care workflows. The company engages in B2B transactions, supplying its liquid biopsy tests to hospitals and laboratories that then offer these services to their patients. Revenue is generated through the sale of its flagship product, the 3D REVEAL™ liquid biopsy, which is expected to be billed per diagnostic test performed. Pricing structures may be defined through subscription agreements or direct sales contracts, ensuring healthcare partners have access to the latest advancements in cancer detection technology. These transactional frameworks are designed to foster long-term relationships with clients, supporting a continuous revenue stream as the demand for early cancer detection solutions grows

## Funding rounds

- Seed, Dec 10, 2025 — New Orleans BioInnovation Center, Boot64 Ventures, Tulane Ventures, 1834 Ventures

## Investors

- New Orleans BioInnovation Center (https://capitalatlas.ai/funds/new-orleans-bioinnovation-center) — Seed
- Boot64 Ventures (https://capitalatlas.ai/funds/boot64-ventures) — Seed
- Tulane Ventures — Seed
- 1834 Ventures (https://capitalatlas.ai/funds/1834-ventures) — Seed